Folic Acid (Pre-conception and Pregnancy)
Brand names: Preconceive, Lexpec (5mg)
Folic acid taken before conception and during early pregnancy as a B-group vitamin supplement, given specifically to reduce the risk of fetal neural tube defects such as spina bifida.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Folic acid is converted to tetrahydrofolate, an essential cofactor for nucleotide synthesis and methylation reactions required for rapid cell division and closure of the neural tube in early embryonic development.
Prescribing in practice
- Supplementation should ideally begin before conception and continue through the first trimester, as the neural tube closes early in pregnancy, before many women know they are pregnant.
- A higher-strength preparation is indicated for women at increased risk, including those with a previous affected pregnancy, diabetes, a high body-mass index, sickle cell disease, or taking antiepileptic or other antifolate medicines.
- Folic acid can mask the haematological signs of vitamin B12 deficiency while allowing neurological damage to progress, so consider B12 status where deficiency is plausible.
Monitoring
Routine biochemical monitoring is not required for standard antenatal supplementation, the focus being on timely initiation and adherence.
Counselling the patient
- Start taking folic acid as soon as you plan a pregnancy, not when you first miss a period.
- Continue daily through the early weeks of pregnancy even if you feel well.
- Tell your clinician if you have epilepsy, diabetes or a previous pregnancy affected by spina bifida, as you may need a stronger dose.
Evidence & guidelines
The landmark MRC Vitamin Study and subsequent guidance established that periconceptional folic acid substantially reduces the risk and recurrence of neural tube defects.
Reference: NICE NG3 Antenatal Care; NICE NG133; PHE Folic Acid Guidance; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Endotracheal Tube Depth and Tidal Volume Calculator · Airway Management
- Framingham Risk Score · Cardiovascular Risk
- SCORE2-Diabetes 10-Year CVD Risk in Type 2 Diabetes · Cardiovascular Risk
- PFO-Associated Stroke Causal Likelihood (PASCAL) Classification · Stroke Prevention
- PCP-HF Risk Score (Pooled Cohort Equations to Prevent Heart Failure) · Heart Failure Prevention
- CHADS-65 Score for Atrial Fibrillation · Atrial Fibrillation
- Spinal Anaesthesia Hypotension Management · AAGBI; ASA
- Pre-Eclampsia / Eclampsia in ED · NICE NG133; RCOG Green-top 10A
- Suspected Ectopic Pregnancy · NICE NG126; RCOG Green-top 21
- Polycystic Ovary Syndrome (PCOS) · International PCOS Guideline 2023; NICE CKS
- Pre-eclampsia Management · NICE NG133 2019
- Ectopic Pregnancy · NICE CG154 / RCOG GTG 21